ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
accruals factor · long-only model fund

Foundry Healthcare Net Operating Assets Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FNOHHYPOTHETICAL MODEL
Since ’99
+142%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Nov 2022
placeholder
Full Sharpe
0.27
Ann. Return (LS)
5.0%
Ann. Volatility
18.5%
Max Drawdown
-65.0%
Test Sharpe ’19–26
0.75
Test FF5 α (ann.)
15.6%
vs Fama-French 5
Test FF5 α t-stat
2.60
significant (|t| ≥ 2)
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
142%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.59
what this fund holds
Long leg ann. return
12.2%
buyable, long-only
Long-short Sharpe
0.27
requires shorting
Bottom bucket ann. return
7.2%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1MCK
MCKESSON CORPHealthcare$101.14B
24.28%
2COR
CENCORA INCHealthcare$59.91B
14.38%
3CAH
CARDINAL HEALTH INCHealthcare$53.52B
12.85%
4CNC
CENTENE CORPHealthcare$32.81B
7.87%
5BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
3.83%
6MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
3.69%
7AXSM
AXSOME THERAPEUTICS INCHealthcare$11.84B
2.84%
8MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
2.82%
9OSCR
OSCAR HEALTH INCHealthcare$8.77B
2.11%
10IMVT
IMMUNOVANT INCHealthcare$8.27B
1.98%
11IBRX
IMMUNITYBIO INCHealthcare$8.04B
1.93%
12RYTM
RHYTHM PHARMACEUTICALS INCHealthcare$7.31B
1.75%
13HNGE
HINGE HEALTH INCHealthcare$6.74B
1.62%
14PTCT
PTC THERAPEUTICS INCHealthcare$6.52B
1.56%
15SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
1.52%
16DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.16%
17ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
1.02%
18IMNM
IMMUNOME INCHealthcare$2.53B
0.61%
19SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
0.59%
20AGL
AGILON HEALTH INCHealthcare$2.17B
0.52%
21PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.48%
22AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.47%
23OCUL
OCULAR THERAPEUTIX INCHealthcare$1.96B
0.47%
24URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.47%
25DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.47%
26BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.42%
27TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.41%
28ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.41%
29CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.40%
30MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.35%
31OMDA
OMADA HEALTH INCHealthcare$1.41B
0.34%
32NVAX
NOVAVAX INCHealthcare$1.35B
0.32%
33INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.31%
34MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.28%
35SDGR
SCHRODINGER INCHealthcare$1.14B
0.27%
36WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.27%
37FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.24%
38VOR
VOR BIOPHARMA INCHealthcare$980M
0.24%
39ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.23%
40KURA
KURA ONCOLOGY INCHealthcare$964M
0.23%
41ANNX
ANNEXON INCHealthcare$950M
0.23%
42TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.21%
43PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.21%
44REPL
REPLIMUNE GROUP INCHealthcare$859M
0.21%
45AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.20%
46CADL
CANDEL THERAPEUTICS INCHealthcare$746M
0.18%
47ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.15%
48TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.15%
49STTK
SHATTUCK LABS INCHealthcare$577M
0.14%
50VSTM
VERASTEM INCHealthcare$530M
0.13%
51ZURA
ZURA BIO LTDHealthcare$518M
0.12%
52NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.12%
53PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.11%
54BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.11%
55TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.10%
56CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.10%
57STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.09%
58FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.09%
59CV
CAPSOVISION INCHealthcare$335M
0.08%
60FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.07%
61SGHT
SIGHT SCIENCES INCHealthcare$274M
0.07%
62QTTB
Q32 BIO INCHealthcare$255M
0.06%
63SRZN
SURROZEN INCHealthcare$255M
0.06%
64RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.06%
65GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.06%
66KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.05%
67KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.05%
68AGEN
AGENUS INCHealthcare$209M
0.05%
69IMUX
IMMUNIC INCHealthcare$207M
0.05%
70DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.05%
71AMWL
AMERICAN WELL CORPHealthcare$199M
0.05%
72TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.05%
73ACOG
ALPHA COGNITION INCHealthcare$185M
0.04%
74ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.04%
75OWLT
OWLET INCHealthcare$162M
0.04%
76RCEL
AVITA MEDICAL INCHealthcare$157M
0.04%
77UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.03%
78PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.03%
79VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.03%
80AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.03%
81JYNT
JOINT CORPHealthcare$127M
0.03%
82SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.03%
83VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.02%
84RLYB
RALLYBIO CORPHealthcare$87M
0.02%
85CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.02%
86NRXS
NEURAXIS INCHealthcare$84M
0.02%
87PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.02%
88ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.02%
89CLNN
CLENE INCHealthcare$76M
0.02%
90SCLX
SCILEX HOLDING COHealthcare$72M
0.02%
91LNSR
LENSAR INCHealthcare$70M
0.02%
92EDSA
EDESA BIOTECH INCHealthcare$59M
0.01%
93INKT
MINK THERAPEUTICS INCHealthcare$53M
0.01%
94XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.01%
95EXOZ
EXOZYMES INCHealthcare$51M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $416.64B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
34%3
34%4
12%7
2%5
3%7
2%5
2%23
1%10
1%11

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 92% toward Large, 37% toward Growth. +10% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt92% → Large
SmallLarge
Value ↔ growth tilt37% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    60.6%
    Margin
    -14.4%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    24.3%
    Margin
    0.7%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.6 (95% CI 1.1-1.9)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
15.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.58x
within
parametric
1.30x
within
cornish fisher
1.44x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 21%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2004
Before publication (pre-2004)
-0.03
Sharpe · -0.8% p.a.
January 1999December 2004 · 72 mo
Since publication
0.49
Sharpe · 6.6% p.a.
January 2005July 2026 · 259 mo
Change in Sharpe+0.52the return flipped from negative to positive since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
77%
20 of 26 3-year windows made money
Worst window
-0.57
Sharpe, January 2012 – December 2014
January 1999July 2026
Median Sharpe
0.44
Dispersion
0.48
Best window
1.30

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.37.0%18.8%
3 yearsp.a.19.1%10.8%
5 yearsp.a.10.1%12.1%
10 yearsp.a.14.0%8.3%
Since inceptionp.a.10.5%3.3%
Calendar years
YearLong legLong-short
20267 mo7.8%3.7%
202543.2%34.2%
20240.2%-11.5%
202320.9%15.4%
2022-8.1%21.4%
202123.4%27.5%
202032.5%7.4%
201922.6%-5.2%
2018-11.2%-10.4%
201734.3%14.4%
2016-16.7%-4.1%
20157.8%6.0%
201425.6%-7.2%
201347.9%-3.3%
201215.6%-6.4%
201116.4%14.5%
201018.0%17.1%
200931.9%10.9%
2008-41.2%-8.5%
200716.6%5.7%
200610.0%2.7%
200521.3%17.0%
20043.9%3.1%
200354.4%13.6%
2002-19.6%8.1%
2001-14.0%-7.3%
200029.6%-16.8%
1999-17.0%-27.1%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FNOH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-11-27 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$416.64B

Methodology

The Foundry Healthcare Net Operating Assets Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Net Operating Assets signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.